| Systematic (IUPAC) name | |
|---|---|
| (8R,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | X |
| Legal status | ℞ Prescription only |
| Routes | oral administration |
| Pharmacokinetic data | |
| Bioavailability | in vitro 99% using 3H=R5020 / in vivo similar to progesterone |
| Half-life | 16 to 18 hrs. |
| Excretion | urinary tract mainly |
| Identifiers | |
| CAS number | 60282-87-3 |
| ATC code | G03AA10 |
| PubChem | CID 3033968 |
| DrugBank | DB06730 |
| ChemSpider | 2298532 |
| UNII | 1664P6E6MI |
| KEGG | D04316 |
| ChEMBL | CHEMBL1213583 |
| Chemical data | |
| Formula | C21H26O2 |
| Mol. mass | 310.430 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Gestodene is a progestogen hormonal contraceptive. Products containing gestodene include:
Contents |
Gestodene is androgenically neutral, meaning that contraceptive pills containing gestodene do not exhibit the androgenic side effects (e.g. acne, hirsutism, weight gain) often associated with second-generation contraceptive pills, such as those containing levonorgestrel.[2]
The synthetic estrogen dosage in third-generation contraceptive pills (including those containing gestodene) is lower than that in second-generation oral contraceptives, reducing the likelihood of weight gain, breast tenderness and migraine.[3]
Third-generation oral contraceptives are also suitable for use in patients with diabetes or lipid disorders because they have minimal impact on blood glucose levels and the lipid profile.[4]
Women who take oral contraceptives containing gestodene are 5.6 times as likely to develop thromboembolism than women who do not take any contraceptive pill, and 1.6 times as likely to develop thromboembolism compared to women taking oral contraceptives containing levonorgestrel.[5]
|
||||||||||||||||||||||||||||||||||||||||||||||||||||